By Josh Beckerman
Shares of Enveric Biosciences shares fell after the company reported a $5 million public offering.
The stock was down 44%, to $2.17, Friday afternoon and are down about 83% over the past 52 weeks.
Shares ended the regular session Thursday at $3.90, and peaked at $6.48 in after-hours trading, according to Nasdaq.com, after the company said it received a Notice of Allowance from the U.S. Patent and Trademark Office.
The patent application pertained to EVM301 molecules being developed as potential treatments for mental-health disorders.
Later Thursday night, the company said a public offering of an aggregate of 1.67 shares, or stock equivalents in lieu thereof, 1.67 million Series A warrants and 1.67 million Series B warrants priced at a combined price of $3 per share or stock equivalent and accompanying warrants.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 31, 2025 13:51 ET (18:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。